Condition: Chikungunya Virus · Sponsor: Bavarian Nordic
Study EBSI-CV-317-007 is a field study to evaluate the efficacy, immunogenicity, and safety of CHIKV VLP vaccine. The study was designed using infectious disease models and advanced analytics to guide region and clinical site prioritization, define the timing of study activities, and optimize the study parameters to local epidemiological conditions for CHIKV disease to overcome the challenges of assessing efficacy for CHIKV VLP vaccine.
This description comes directly from the study's public registry record.
Anjali Chudasama, MPH M.Sc. · 844-422-8274 · info@bavarian-nordic.com
Tiffany Brockington · info@bavarian-nordic.com
Always discuss trial participation with your own doctor first.
| WRAIR-AFRIMS Philippines, Cebu (WRAIR-APC) | Cebu City, Cebu, Philippines | Recruiting |
| Kamphaeng Phet Provincial Hospital | Kamphaeng Phet, Changwat Kamphaeng Phet, Thailand | Recruiting |
| Songklanagarind hospital, Prince of Songkla University (PSU) | Hat Yai, Changwat Songkhla, Thailand | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07467707